Search | Clinical Trials Finder

Conditions: COVID-19
Interventions: RBT-9 (90 mg), 0.9% sodium chloride (normal saline); Drug
Lead sponsor: Renibus Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 5
States / cities: New Smyrna Beach, Florida • Berkley, Michigan • El Paso, Texas + 2 more

Conditions: Solid Tumor
Interventions: Decitabine, Cedazuridine; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 2
States / cities: Los Angeles, California • Baltimore, Maryland

Conditions: Heart Failure, HFpEF, HFpEF - Heart Failure With Preserved Ejection Fraction
Interventions: Placebo (matching), Beta-blockers; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Von Willebrand Disease (VWD)
Interventions: Vonicog Alfa, ADVATE; Biological
Lead sponsor: Takeda; Industry
Eligibility: Up to 17 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 12
States / cities: Birmingham, Alabama • Orlando, Florida • Peoria, Illinois + 9 more

Conditions: Breast Cancer, Metastatic HER2-negative Breast
Interventions: Cyclophosphamide, Mesothelin-targeted T cells, AP1903; Drug · Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 186 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: HIV Infections
Interventions: DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 334 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2020
U.S. locations: 8
States / cities: Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Typhoid VI Polysaccharide Vaccine Injectable Solution, Saline Placebo (0.5mL injection); Biological · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 288 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: bortezomib, temozolomide, pharmacological study; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2012
U.S. locations: 2
States / cities: Duarte, California • Pasadena, California

Conditions: Amyotrophic Lateral Sclerosis
Interventions: [11C]CPPC Injection; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hypoactive Sexual Desire Disorder
Interventions: Placebo, Sildenafil, Testosterone; Drug
Lead sponsor: Emotional Brain NY Inc.; Industry
Eligibility: 21 Years to 70 Years · Female only
Enrollment: 196 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 14
States / cities: San Diego, California • Washington D.C., District of Columbia • Brooksville, Florida + 11 more

Conditions: Head and Neck Cancer
Interventions: Pemetrexed plus Gemcitabine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Pancreatitis, Acute
Interventions: Pirfenidone Oral Tablet, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 85 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Birmingham, Alabama • Rochester, Minnesota

Conditions: Metastatic Cancer, Solid Tumor
Interventions: Sym021, Sym024; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Grand Rapids, Michigan • Houston, Texas • San Antonio, Texas

Conditions: Cancer Metastatic, Metastatic Solid Tumor
Interventions: Zeaxanthin, Zeaxanthin Plus Pembrolizumab; Biological · Combination Product
Lead sponsor: Valley Health System; Other
Eligibility: 18 Years to 99 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Paramus, New Jersey

Conditions: Obesity, Overweight, Type 2 Diabetes Mellitus
Interventions: Maridebart Cafraglutide, Placebo; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 592 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 29
States / cities: Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 20 more

Conditions: Hyperglycemia
Interventions: Sitagliptin, Placebo, Supplemental insulin (insulin lispro), Supplemental insulin (insulin aspart), Long acting basal insulin (insulin detemir), Long acting basal insulin (insulin glargine); Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: HIV Infections
Interventions: Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 16 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1997 – 2002
U.S. locations: 25
States / cities: Long Beach, California • Los Angeles, California • Oakland, California + 16 more

Conditions: HIV Infections
Interventions: ibalizumab 800mg Q2Weeks, ibalizumab 2000mg Q4Weeks; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Acute Myeloid Leukemia
Interventions: ASLAN003; Drug
Lead sponsor: ASLAN Pharmaceuticals; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Louisville, Kentucky

Conditions: Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, Myelodysplastic Syndrome
Interventions: Clofarabine/Busulfan x 4, Peripheral blood stem cell transplant, Total Lymphoid Irradiation; Drug · Procedure · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions: anti-thymocyte globulin, cyclophosphamide, cyclosporine, fludarabine phosphate, mycophenolate mofetil, umbilical cord blood transplantation, total body irradiation; Biological · Drug · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 69 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Relapsed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia
Interventions: Acalabrutinib, Umbralisib, Ublituximab; Drug
Lead sponsor: Jennifer R. Brown, MD, PhD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Cancer, Ovarian Neoplasms
Interventions: Vigil, Placebo; Biological · Other
Lead sponsor: Gradalis, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 26
States / cities: Mobile, Alabama • Irvine, California • San Francisco, California + 22 more

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 148
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Search by objective public record fields.

A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study)

Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors

Deprescribing Beta-Blockers in Elders With Heart Failure With Preserved Ejection Fraction (DEPRESCRIBE-HFpEF)

A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)

T-Cell Therapy for Advanced Breast Cancer

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

Inflammatory Challenge and Fear

Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS

Lybrido for Female Sexual Dysfunction

A Phase II Study of Pemetrexed Plus Gemcitabine for Metastatic/Recurrent Head and Neck Cancer (HNSCC)

Safety and Tolerability of Pirfenidone in Acute Pancreatitis

Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies

Determine Safety & Recommended Phase 2 Dosing of Zeaxanthin Alone or in Combination w/Pembrolizumab in Patients With Metastatic Cancer

Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Sitagliptin in Non-Diabetic Patients Undergoing General Surgery

Safety, Tolerability, and Anti-HIV Activity of DMP 266 (Efavirenz) in Combination With Nelfinavir in HIV-Positive Children

Investigator-Sponsored Protocol - Continued Use of Ibalizumab

A Dose Optimisation Study of ASLAN003 in Acute Myeloid Leukemia

Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen

Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease

Acalabrutinib, Umbralisib, and Ublituximab (AU2) In Relapsed and Untreated CLL

A Trial of Vigil for Participants With Ovarian Cancer

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)